Obesity-enhanced colon cancer: Functional food compounds and their mechanisms of action

Jairam Vanamala, Christopher C. Tarver, Peter S. Murano

Research output: Contribution to journalReview article

19 Citations (Scopus)

Abstract

Obesity is rapidly becoming a global phenomenon. This is more than a cosmetic issue as obesity is associated with several life-threatening diseases, including colon cancer. Insulin resistance and inflammation, underlying factors in obesity-related diseases, promote colonocyte proliferation and suppress programmed cell death, or apoptosis, by activating the insulin-like growth factor (IGF) and prostaglandin pathways. These pathways converge on the Wnt pathway, which is implicated in colon carcinogenesis. Despite tremendous advances in our understanding of the molecular mechanisms involved in colon carcinogenesis, mortality due to colon cancer world-wide is unacceptably high. Even though conventional therapies can prolong a patient's life-span a few years, they cause serious side effects. Thus, there is growing interest in functional foods and dietary bioactive compounds with chemopreventive properties. This search is fueled by the epidemiological studies indicating that plant-based diets are protective against several types of cancers. This review provides a brief summary of the IGF and prostaglandin pathways, which are implicated in obesity-enhanced colon cancer, and some of the functional foods/dietary compounds that target these pathways. It is essential to understand the molecular mechanisms involved in chemoprevention before providing appropriate science-based dietary recommendations to prevent colon cancer in both obese and non-obese individuals.

Original languageEnglish (US)
Pages (from-to)611-633
Number of pages23
JournalCurrent Cancer Drug Targets
Volume8
Issue number7
DOIs
StatePublished - Nov 1 2008

Fingerprint

Functional Food
Colonic Neoplasms
Obesity
Somatomedins
Prostaglandins
Colon
Carcinogenesis
Wnt Signaling Pathway
Chemoprevention
Cosmetics
Insulin Resistance
Epidemiologic Studies
Cell Death
Apoptosis
Diet
Inflammation
Mortality
Neoplasms
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pharmacology
  • Drug Discovery
  • Cancer Research

Cite this

Vanamala, Jairam ; Tarver, Christopher C. ; Murano, Peter S. / Obesity-enhanced colon cancer : Functional food compounds and their mechanisms of action. In: Current Cancer Drug Targets. 2008 ; Vol. 8, No. 7. pp. 611-633.
@article{6b156d137dce497da7cae64a17889167,
title = "Obesity-enhanced colon cancer: Functional food compounds and their mechanisms of action",
abstract = "Obesity is rapidly becoming a global phenomenon. This is more than a cosmetic issue as obesity is associated with several life-threatening diseases, including colon cancer. Insulin resistance and inflammation, underlying factors in obesity-related diseases, promote colonocyte proliferation and suppress programmed cell death, or apoptosis, by activating the insulin-like growth factor (IGF) and prostaglandin pathways. These pathways converge on the Wnt pathway, which is implicated in colon carcinogenesis. Despite tremendous advances in our understanding of the molecular mechanisms involved in colon carcinogenesis, mortality due to colon cancer world-wide is unacceptably high. Even though conventional therapies can prolong a patient's life-span a few years, they cause serious side effects. Thus, there is growing interest in functional foods and dietary bioactive compounds with chemopreventive properties. This search is fueled by the epidemiological studies indicating that plant-based diets are protective against several types of cancers. This review provides a brief summary of the IGF and prostaglandin pathways, which are implicated in obesity-enhanced colon cancer, and some of the functional foods/dietary compounds that target these pathways. It is essential to understand the molecular mechanisms involved in chemoprevention before providing appropriate science-based dietary recommendations to prevent colon cancer in both obese and non-obese individuals.",
author = "Jairam Vanamala and Tarver, {Christopher C.} and Murano, {Peter S.}",
year = "2008",
month = "11",
day = "1",
doi = "10.2174/156800908786241087",
language = "English (US)",
volume = "8",
pages = "611--633",
journal = "Current Cancer Drug Targets",
issn = "1568-0096",
publisher = "Bentham Science Publishers B.V.",
number = "7",

}

Obesity-enhanced colon cancer : Functional food compounds and their mechanisms of action. / Vanamala, Jairam; Tarver, Christopher C.; Murano, Peter S.

In: Current Cancer Drug Targets, Vol. 8, No. 7, 01.11.2008, p. 611-633.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Obesity-enhanced colon cancer

T2 - Functional food compounds and their mechanisms of action

AU - Vanamala, Jairam

AU - Tarver, Christopher C.

AU - Murano, Peter S.

PY - 2008/11/1

Y1 - 2008/11/1

N2 - Obesity is rapidly becoming a global phenomenon. This is more than a cosmetic issue as obesity is associated with several life-threatening diseases, including colon cancer. Insulin resistance and inflammation, underlying factors in obesity-related diseases, promote colonocyte proliferation and suppress programmed cell death, or apoptosis, by activating the insulin-like growth factor (IGF) and prostaglandin pathways. These pathways converge on the Wnt pathway, which is implicated in colon carcinogenesis. Despite tremendous advances in our understanding of the molecular mechanisms involved in colon carcinogenesis, mortality due to colon cancer world-wide is unacceptably high. Even though conventional therapies can prolong a patient's life-span a few years, they cause serious side effects. Thus, there is growing interest in functional foods and dietary bioactive compounds with chemopreventive properties. This search is fueled by the epidemiological studies indicating that plant-based diets are protective against several types of cancers. This review provides a brief summary of the IGF and prostaglandin pathways, which are implicated in obesity-enhanced colon cancer, and some of the functional foods/dietary compounds that target these pathways. It is essential to understand the molecular mechanisms involved in chemoprevention before providing appropriate science-based dietary recommendations to prevent colon cancer in both obese and non-obese individuals.

AB - Obesity is rapidly becoming a global phenomenon. This is more than a cosmetic issue as obesity is associated with several life-threatening diseases, including colon cancer. Insulin resistance and inflammation, underlying factors in obesity-related diseases, promote colonocyte proliferation and suppress programmed cell death, or apoptosis, by activating the insulin-like growth factor (IGF) and prostaglandin pathways. These pathways converge on the Wnt pathway, which is implicated in colon carcinogenesis. Despite tremendous advances in our understanding of the molecular mechanisms involved in colon carcinogenesis, mortality due to colon cancer world-wide is unacceptably high. Even though conventional therapies can prolong a patient's life-span a few years, they cause serious side effects. Thus, there is growing interest in functional foods and dietary bioactive compounds with chemopreventive properties. This search is fueled by the epidemiological studies indicating that plant-based diets are protective against several types of cancers. This review provides a brief summary of the IGF and prostaglandin pathways, which are implicated in obesity-enhanced colon cancer, and some of the functional foods/dietary compounds that target these pathways. It is essential to understand the molecular mechanisms involved in chemoprevention before providing appropriate science-based dietary recommendations to prevent colon cancer in both obese and non-obese individuals.

UR - http://www.scopus.com/inward/record.url?scp=55449099572&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55449099572&partnerID=8YFLogxK

U2 - 10.2174/156800908786241087

DO - 10.2174/156800908786241087

M3 - Review article

C2 - 18991570

AN - SCOPUS:55449099572

VL - 8

SP - 611

EP - 633

JO - Current Cancer Drug Targets

JF - Current Cancer Drug Targets

SN - 1568-0096

IS - 7

ER -